VBI Vaccines Inc./BC (VBIV) is a biopharmaceutical company that is committed to developing novel vaccines to address unmet needs in infectious disease and immuno-oncology. The company was founded in 2001 and is headquartered in Cambridge, Massachusetts, with additional research facilities located in Ottawa, Canada. VBI Vaccines is known for being at the forefront of vaccine research and development, leveraging its proprietary technology platforms to create vaccines that are both safe and highly effective.
The company is dedicated to addressing global public health and unmet needs in cancer care. To do this, VBI Vaccines has adopted a unique scientific approach that puts a strong emphasis on understanding the molecular structure of viruses and how they interact with the human immune system. This research methodology aids the company in creating effective vaccines that stimulate robust and durable immune responses.
VBI Vaccines has a diverse and promising pipeline of product candidates. This includes Sci-B-Vac®, a commercial-stage product that is a highly-potent, third-generation hepatitis B (HBV) vaccine. Other key candidates in clinical stages include VBI-1901, their unique cancer vaccine candidate for the treatment of glioblastoma, one of the most common and aggressive types of brain cancer.
VBI Vaccines has also ventured into the fight against the COVID-19 pandemic. The company has a novel coronavirus program, VBI-2902, that is aimed at developing a pan-coronavirus vaccine candidate to target future emergent coronavirus strains.
Besides the innovative product development, another distinguishable feature of VBI Vaccines is its advanced eVLP (enveloped Virus-Like Particle) technology. This unique platform allows the company to design potential vaccine candidates that mimic the structure of viruses contributing to improved immunity.
Throughout its existence, VBI Vaccines has managed to reinforce a strong commitment to patient-centric innovation. The company prioritizes developing novel, safer vaccines that provide broad coverage and effective immune responses, all in the sight to improving individual health and global public health.
As VBI Vaccines continues to grow, its relentless dedication to research and development promises a brighter, healthier future where the impact of infectious diseases and certain cancers can be significantly reduced, or even eradicated. Even though the company faces stiff competition in the vaccine market, its commitment to innovative science, patient-focused product development, and its unique technology platforms keep it at the forefront of the vaccine industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
VBI Vaccines announced its full-year 2023 financial results, showcasing significant growth in PreHevbrio net revenue, which increased by 234% year-over-year. The company also highlighted encouraging early data from its Phase 2b study of VBI-1901 for recurrent glioblastoma and outlined upcoming milestones for its pipeline programs. Alongside financial improvements, VBI Vaccines detailed strategic partnerships and efforts to reduce debt, positioning for sustainable growth.
VBI Vaccines is recalling its hepatitis B vaccine, PreHevbrio, and requesting its immediate destruction as the company winds down operations after filing for bankruptcy. The recall comes after the company, which had been seeking a sale for its assets, reported only $3.1 million in PreHevbrio sales in 2023 and had previously slimmed down its workforce and sold its hepatitis B vaccine candidate to Brii Biosciences.